CYTK Cytokinetics, Incorporated

NASDAQ
$65.60

Cytokinetics, Incorporated (CYTK) Insider Activity

What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.

Insider signal Moderately bearish Selling ran elevated versus CYTK's own trailing one-year pace, with 2% of sale value under a prearranged plan.
Cluster activity 0 buyers in the last 30 days 0 buyers in the last 90 days 5 sellers in the last 90 days
Insiders buying
0
0 transactions
Insiders selling
9
45 transactions
Purchases
$0
0 shares
Sales
$32.2M
436,912 shares
Net activity
-$32.2M
purchases less sales

How much of that selling was preplanned? 2% planned / 98% discretionary

10b5-1 plan sales $550.8K 1 transaction · 7,500 shares
Discretionary sales $31.7M 44 transactions · 429,412 shares

Largest single sale: $6.8M.

Where they traded

Buy Sell Dot area is proportional to transaction value.

No open-market insider purchase on record.

Recent open-market activity

Date Insider Role Action Shares Price Value Held after
Blum Robert I President & CEO Sell 7,500 $65.46 $491.0K 278,544 −2.6% of holding
Malik Fady Ibraham EVP Research & Development Sell 3,500 $68.29 $239.0K 153,902 −2.2% of holding
Blum Robert I President & CEO Sell 97,926 $69.33 $6.8M None left
Landry Robert E Director Sell 1,000 $72.13 $72.1K 8,184 −10.9% of holding
Blum Robert I President & CEO Sell 10b5-1 7,500 $73.44 $550.8K 377,820 −1.9% of holding
Landry Robert E Director Sell 1,000 $74.66 $74.7K 9,184 −9.8% of holding
Malik Fady Ibraham EVP Research & Development Sell 3,500 $75.46 $264.1K 153,902 −2.2% of holding
PARSHALL B LYNNE Director Sell 5,000 $71.48 $357.4K 10,784 −31.7% of holding
Callos Andrew EVP, Chief Commercial Officer Sell 10,000 $70.24 $702.4K 58,555 −14.6% of holding
Blum Robert I President & CEO Sell 7,500 $70.24 $526.8K 377,820 −1.9% of holding
Malik Fady Ibraham EVP Research & Development Sell 3,500 $75.82 $265.4K 153,902 −2.2% of holding
Blum Robert I President & CEO Sell 7,500 $76.76 $575.7K 377,820 −1.9% of holding
Callos Andrew EVP, Chief Commercial Officer Sell 14,000 $79.88 $1.1M 58,555 −19.3% of holding
Blum Robert I President & CEO Sell 7,500 $80.87 $606.5K 377,820 −1.9% of holding
Malik Fady Ibraham EVP Research & Development Sell 3,500 $80.59 $282.1K 153,902 −2.2% of holding
Blum Robert I 2 fills President & CEO Sell 7,500 $82.02 $615.2K 377,820 −1.9% of holding
Malik Fady Ibraham EVP Research & Development Sell 3,500 $86.62 $303.2K 153,902 −2.2% of holding
Callos Andrew EVP, Chief Commercial Officer Sell 15,000 $85.80 $1.3M 58,555 −20.4% of holding
Blum Robert I President & CEO Sell 7,500 $84.92 $636.9K 377,830 −1.9% of holding
Lee Sung EVP, Chief Financial Officer Sell 1,112 $87.79 $97.6K 63,221 −1.7% of holding
Lee Sung EVP, Chief Financial Officer Sell 3,134 $85.00 $266.4K 63,221 −4.7% of holding
Lee Sung EVP, Chief Financial Officer Sell 38,730 $82.30 $3.2M 63,221 −38% of holding
Malik Fady Ibraham EVP Research & Development Sell 3,500 $79.51 $278.3K 153,902 −2.2% of holding
Blum Robert I President & CEO Sell 7,500 $70.46 $528.5K 385,330 −1.9% of holding
Malik Fady Ibraham EVP Research & Development Sell 3,500 $67.98 $237.9K 153,902 −2.2% of holding
Callos Andrew EVP, Chief Commercial Officer Sell 15,000 $74.08 $1.1M 58,555 −20.4% of holding
PARSHALL B LYNNE Director Sell 5,000 $74.08 $370.4K 15,784 −24.1% of holding
Kaye Edward M. MD Director Sell 2,933 $76.09 $223.2K 10,283 −22.2% of holding
Blum Robert I President & CEO Sell 7,500 $77.21 $579.1K 392,830 −1.9% of holding
Malik Fady Ibraham EVP Research & Development Sell 3,500 $75.69 $264.9K 153,902 −2.2% of holding
Blum Robert I President & CEO Sell 7,500 $77.92 $584.4K 400,330 −1.8% of holding
Lee Sung EVP, Chief Financial Officer Sell 23,906 $76.87 $1.8M 63,221 −27.4% of holding
HENDERSON JOHN T Director Sell 20,000 $75.97 $1.5M 75,237 −21% of holding
Callos Andrew EVP, Chief Commercial Officer Sell 11,333 $77.25 $875.5K 58,555 −16.2% of holding
WIERENGA WENDELL Director Sell 4,032 $75.00 $302.4K 32,637 −11% of holding
Malik Fady Ibraham EVP Research & Development Sell 3,500 $77.37 $270.8K 153,902 −2.2% of holding
Callos Andrew EVP, Chief Commercial Officer Sell 15,857 $65.00 $1.0M 58,555 −21.3% of holding
Callos Andrew EVP, Chief Commercial Officer Sell 15,000 $63.26 $948.9K 58,555 −20.4% of holding
Blum Robert I President & CEO Sell 7,500 $59.62 $447.2K 407,830 −1.8% of holding
Malik Fady Ibraham EVP Research & Development Sell 3,500 $65.69 $229.9K 153,902 −2.2% of holding
Callos Andrew EVP, Chief Commercial Officer Sell 7,449 $66.02 $491.8K 58,555 −11.3% of holding
Blum Robert I President & CEO Sell 7,500 $65.38 $490.4K 415,330 −1.8% of holding
Malik Fady Ibraham 2 fills EVP Research & Development Sell 4,500 $65.11 $293.0K 153,902 −2.8% of holding

Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.